An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma

Malpica, Luis; Castro, Denisse; Enríquez, Daniel; Oviedo-Pecho, Roberto; Peña, Camila; Idrobo, Henry; Fiad, Lorena; Prates, María Virginia; Valcárcel, Bryan; Paredes, Antonio; Sánchez, Gadwyn; Moises, Celia; Castillo, Jorge J.; Villela, Luis; Ramos, Juan Carlos; Biglione, Mirna; Beltrán, Brady E; Linfoproliferativos, Grupo de Estudio Latinoamericano de

doi:10.1080/10428194.2021.1984455

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultimately, we obtained 15 reports regarding the treatment of ATLL, which were performed between 2004 and 2022 (Fig. 1 ) [ 12 – 26 ]. Five of them were conference abstracts.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis

Shafiee

Seighali

Taherzadeh-Ghahfarokhi

et al. 2023

Virol J

View full text Add to dashboard Cite

Background ATLL (Adult T-Cell Leukemia/Lymphoma) is an aggressive hematological malignancy. This T-cell non-Hodgkin lymphoma, caused by the human T-cell leukemia virus type 1 (HTLV-1), is challenging to treat. There is no known treatment for ATLL as of yet. However, it is recommended to use Zidovudine and Interferon Alfa-based regimens (AZT/IFN), chemotherapy, and stem cell transplant. This study aims to review the outcome of patients with different subtypes of ATLL treated with Zidovudine and Interferon Alfa-based regimens. Methods A systematic search was carried out for articles evaluating outcomes of ATLL treatment by AZT/IFN agents on human subjects from January 1, 2004, until July 1, 2022. Researchers assessed all studies regarding the topic, followed by extracting the data. A random-effects model was used in the meta-analyses. Results We obtained fifteen articles on the AZT/IFN treatment of 1101 ATLL patients. The response rate of the AZT/IFN regimen yielded an OR of 67% [95% CI: 0.50; 0.80], a CR of 33% [95% CI: 0.24; 0.44], and a PR of 31% [95% CI: 0.24; 0.39] among individuals who received this regimen at any point during their treatment. Our subgroup analyses’ findings demonstrated that patients who received front-line and combined AZT/IFN therapy responded better than those who received AZT/IFN alone. It is significant to note that patients with indolent subtypes of disease had considerably higher response rates than individuals with aggressive disease. Conclusion IFN/AZT combined with chemotherapy regimens is an effective treatment for ATLL patients, and its use in the early stages of the disease may result in a greater response rate.

show abstract

“…Ultimately, we obtained 15 reports regarding the treatment of ATLL, which were performed between 2004 and 2022 (Fig. 1 ) [ 12 – 26 ]. Five of them were conference abstracts.…”

Section: Resultsmentioning

confidence: 99%

“…Data on the complete response rate (CR) of ATLL patients who received AZT/IFN-based regimens were synthesized from 11 studies and the results were included in Fig. 4 [ 12 – 14 , 16 , 18 , 21 – 26 ]. Two hundred thirty-nine out of 1101 patients were included.…”

Section: Resultsmentioning

confidence: 99%

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis

Shafiee

Seighali

Taherzadeh-Ghahfarokhi

et al. 2023

Virol J

View full text Add to dashboard Cite

show abstract

“…ATL is classified into indolent types (smoldering and chronic) and aggressive types (acute and lymphoma). Patients with aggressive ATL have a median survival time of less than one year, and those with indolent ATL often undergo a blast crisis after several years [3][4][5][6][7]. Approximately 5-10 million individuals are infected with HTLV-1 (carriers) worldwide, and they are geographically concentrated mainly in Japan, South America, Africa, and the Caribbean islands.…”

Section: Introductionmentioning

confidence: 99%

Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review

Nakahata,

Enriquez-Vera,

Jahan

et al. 2023

Preprint

View full text Add to dashboard Cite

Human T-cell leukemia virus type-1 (HTLV-1) is the causative agent of adult T-cell leukemia/lymphoma (ATL). HTLV-1 carriers have a life-long asymptomatic balance between infected cells and host antiviral immunity, but 5–10% of carriers lose this balance and develop ATL. Coinfection with Strongyloides also promotes ATL development, suggesting that the immunological status of infected individuals is a determinant of viral pathogenicity. As CD4+ T cells play a central role in host immunity, deregulation of their function and differentiation by HTLV-1 promotes the immune evasion of infected T cells. During ATL development, the accumulation of genetic and epigenetic alterations in key host immunity-related genes further disturbs immunological conditions. Various therapeutic approaches have been developed to treat these abnormalities. Allogeneic hematopoietic stem cell transplantation is currently the only treatment with the potential to cure ATL; however, the patient's immune state may also contribute to its outcome. Additionally, the activity of the anti-CC chemokine receptor 4 antibody, mogamulizumab, also depends on immune functions, such as antibody-dependent cytotoxicity. In this review, we comprehensively summarize the immunological pathogenesis of HTLV-1 infection in ATL and integrate clinical findings to determine the factors to be considered for developing treatment strategies for ATL.

show abstract

Stem Cell Therapy for HTLV-1 Induced Adult T-Cell Leukemia/Lymphoma (ATLL): A Comprehensive Review

Gholamzad,

Khakpour,

Gholamzad

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma

Cited by 5 publications

References 28 publications

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis

Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review

Stem Cell Therapy for HTLV-1 Induced Adult T-Cell Leukemia/Lymphoma (ATLL): A Comprehensive Review

Contact Info

Product

Resources

About